Skip to main content

Table 7 Clinical performance of triaging hrHPV+ women with HPV16/18 genotyping and using LBC to triage OHR

From: Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies

Study Sensitivity (CIN2+) Specificity (CIN2+) Relative cost of Comparator 2
ATHENA (Wright T et al., 2014 [27]) 93.3% 62.8% − 24%
ATHENA (Castle PE et al., 2011 [28]) 51.8% 75.3% − 24%
POBASCAM (Dijkstra M et al., 2013 [32]) 90.3% 57.6% −25%
PavDag (Stanczuk GA. et al., 2017 [33]) 93.3% 52.7% −24%